Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Mass Spec Predicts Improved Response to Anti-HER2 Therapy in Breast Cancer

Published: Monday, July 07, 2014
Last Updated: Monday, July 07, 2014
Bookmark and Share
Immunohistochemistry is the standard technique for detecting HER2 protein expression, it does not provide absolute quantification of this receptor and is prone to false-positives.

A collaborative study between OncoPlex Diagnostics, Vall d´Hebron Institute of Oncology (VHIO), and Memorial Sloan Kettering Cancer Center, with support from the BBVA Foundation, defined for the first time a quantitative HER2 protein level measured by mass spectrometry is associated with longer disease free and overall survival in patients receiving anti-HER2 treatment.   Results of the study were presented during the ASCO 2014 Annual Meeting by Dr. Paolo Nuciforo, Principal Investigator of VHIO´s Molecular Oncology Group. 

While immunohistochemistry (IHC) is the standard technique for detecting HER2 protein expression, it does not provide absolute quantification of this receptor and is prone to false-positives. Many patients who are classified by IHC as HER2-positive actually express low levels of the receptor which dramatically reduces efficacy of anti-HER2 therapy. 

OncoPlex Diagnostics uses the patented Liquid Tissue® process to solubilize formalin-fixed, paraffin-embedded (FFPE) tissue for precise protein quantitation by mass spectrometry analysis.  The study analyzed tissue from 60 breast cancer patients previously classified as IHC 3+ and treated with anti-HER2 therapy.  The research revealed high variability in HER2 expression within the patient population that had been homogenously classified as 3+ by IHC. Patients with HER2 protein levels greater than or equal to 2758.75 amol/ug, as measured by mass spectrometry, correlated with greater clinical benefit including prolonged survival rates.  The ASCO poster presentation is available at OncoPlex Dx HER2 ASCO2014 Collaboration.

"This study provides evidence that quantitative measurement by mass spectrometry of a tumor-driving protein such as HER2 correlates with the clinical benefit associated with HER2 targeted therapy," stated Dr. Jedd Levine, Chief Medical Officer for OncoPlex Diagnostics. The primary investigator, Dr. Nucifiro, explains, "If future (ongoing) studies enrolling a greater number of patients confirm these results, this would represent an important game-changer in how we currently determine HER2 expression levels as well as provide oncologists with further insight to better tailor anti-HER2-based therapies according to HER2 protein levels."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
MRIs for Fetal Health
Algorithm could help analyze fetal scans to determine whether interventions are warranted.
Illumina Contributes to ClinVar Database
The contribution includes variants of all classifications, from pathogenic to benign, identified during interpretation of whole genome sequences generated in the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Supercomputers Could Improve Cancer Diagnostics
Researchers push the boundaries of cancer research through high-performance computing to map the human immunone.
Transgenomic, Precipio Diagnostics Merger
Merger will creates a robust diagnostic platform focused on improving accuracy of cancer diagnoses.
Inflammation Test May Predict Cardiovascular Disease
An assessment combining measures of immune-cell responsiveness predicted cardiovascular problems in individuals who likely would have slipped under the radar.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Potential Urine Test for CJD
Researchers at the Medical Research Council (MRC) Prion Unit at UCL have found that it may be possible to determine whether or not a person has sporadic Creutzfeldt-Jakob Disease (sCJD) by testing their urine for the presence of abnormal prion proteins.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos